Home Hyperhomocysteinaemia in Patients with Peripheral Arterial Occlusive Disease
Article
Licensed
Unlicensed Requires Authentication

Hyperhomocysteinaemia in Patients with Peripheral Arterial Occlusive Disease

  • Sylvia de Jong
Published/Copyright: June 1, 2005
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 39 Issue 8

Abstract

In the Western world, cardiovascular disease is still the most common cause of death. Over the past decade it has become clear that apart from common risk factors, high concentrations of total homocysteine are relavant to the process of atherosclerosis, especially in the development of premature vascular disease. Hyperhomocysteinaemia (HHC) can be found in 25–32% of the patients with premature peripheral arterial occlusive disease (PAD). Retrospective and prospective studies, evaluating the clinical course of patients with PAD, showed significant associations between high concentrations of total homocysteine and the severity of atherosclerosis and with a more rapid disease progression and mortality rates.

HHC can be treated with vitamin B6 and folic acid. Although there may be indications that there is a protective effect of treatment, prospective randomized clinical trials are urgently needed to unravel the role of HHC and its treatment in patients with premature PAD.

:
Published Online: 2005-06-01
Published in Print: 2001-08-31

Copyright © 2001 by Walter de Gruyter GmbH & Co. KG

Articles in the same Issue

  1. Historical Aspects and Perspectives in Homocysteine Research
  2. The Importance of Hyperhomocysteinemia as a Risk Factor for Diseases: An Overview
  3. Pre-analytical Conditions Affecting the Determination of the Plasma Homocysteine Concentration
  4. Total Plasma Homocysteine and Related Amino Acids in End-Stage Renal Disease (ESRD) Patients Measured by Gas Chromatography-Mass Spectrometry – Comparison with the Abbott IMx Homocysteine Assay and the HPLC Method
  5. Is Hyperhomocysteinemia due to the Oxidative Depletion of Folate rather than to Insufficient Dietary Intake?
  6. Hyperhomocysteinemia in Advanced Age
  7. Genetic Defects as Important Factors for Moderate Hyperhomocysteinemia
  8. Heterogeneity of the Association between Plasma Homocysteine and Atherothrombotic Disease: Insights from Studies of Vascular Structure and Function
  9. Hyperhomocysteinemia as a Risk Factor for Venous Thrombosis
  10. Hyperhomocysteinaemia in Patients with Peripheral Arterial Occlusive Disease
  11. Homocysteine, Vascular Dementia and Alzheimer's Disease
  12. Homocysteine in Cerebrovascular Disease: an Independent Risk Factor for Subcortical Vascular Encephalopathy
  13. Vascular Dysfunction in Hyperhomocyst(e)inemia. Implications for Atherothrombotic Disease
  14. Hyperhomocysteinemia in Chronic Renal Failure Patients: Relation to Nutritional Status and Cardiovascular Disease
  15. Homocysteine, Cystathionine, Methylmalonic Acid and B-Vitamins in Patients with Renal Disease
  16. Hyperhomocysteinemia Is Related to Residual Glomerular Filtration and Folate, but not to Methylenetetrahydrofolate-Reductase and Methionine Synthase Polymorphisms, in Supplemented End-Stage Renal Disease Patients Undergoing Hemodialysis
  17. Effect of Treatment of Hypothyroidism on the Plasma Concentrations of Neuroactive Steroids and Homocysteine
  18. Hyperhomocysteinaemia and Human Reproduction
  19. Homocysteine in Postmenopausal Women and the Importance of Hormone Replacement Therapy
  20. Does a Single Vitamin B-Supplementation Induce Functional Vitamin B-Deficiency?
  21. IFCC News – July 2001
Downloaded on 14.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2001.118/html
Scroll to top button